The Effect of Atorvastatin 80 Mg on Hs-CRP/Albumin Ratio in Reducing Thrombus Burden in PCI-STEMI Patients
Launched by UNIVERSITAS SEBELAS MARET · Mar 6, 2025
Trial Information
Current as of April 23, 2025
Completed
Keywords
ClinConnect Summary
This study encompasses 40 STEMI patients who underwent primary PCI at Dr. Moewardi General Hospital in Central Java, Indonesia, between September and October. This study employed an experimental design with a pre-and-post technique, with participants recruited through sequential sampling. Patients were subsequently allocated into two groups via a double-blind randomization method. A treatment group was administered a loading dose of high-intensity statin (80 mg atorvastatin) upon initial presentation at the emergency department (ED), whereas the control group received no such intervention. ...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • STEMI with onset less than 24 hour and undergo a Primary PCI
- Exclusion Criteria:
- • STEMI beyond 24 hours from the onset of chest pain
- • Prior statin therapy within the preceding 24 hours
- • Hypersensitivity to statins, pregnancy, lactation, severe inflammatory conditions including active liver dysfunction, chronic kidney disease (eGFR \<30 mL/min), autoimmune disorders, malignancy, severe malnutrition, and
- • Contraindications to statin administration.
About Universitas Sebelas Maret
Universitas Sebelas Maret (UNS) is a prominent educational institution in Indonesia, committed to advancing research and innovation in various fields, including health sciences. With a strong emphasis on clinical research, UNS strives to enhance medical knowledge and improve patient care through rigorous scientific investigation. The university collaborates with multiple stakeholders, including healthcare providers and governmental bodies, to conduct clinical trials that adhere to ethical standards and contribute to global health advancements. UNS is dedicated to fostering a culture of excellence in research, training future healthcare professionals, and addressing pressing health challenges in the community and beyond.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Surakarta, Jawa Tengah, Indonesia
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported